Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience.

@article{Laharie2013ImpactOM,
  title={Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience.},
  author={David Laharie and J{\'e}r{\^o}me Filippi and X Roblin and St{\'e}phane Nancey and J-B Chevaux and Xavier A H{\'e}buterne and Bernard Flouri{\'e} and Maylis Capdepont and Laurent Peyrin-Biroulet},
  journal={Alimentary pharmacology & therapeutics},
  year={2013},
  volume={37 10},
  pages={998-1004}
}
BACKGROUND Mucosal healing can be achieved with infliximab (IFX). AIM To assess the impact of mucosal healing on long-term outcomes in patients with ulcerative colitis (UC) when treated with infliximab (IFX) beyond 1 year. METHODS All consecutive adult patients with refractory UC receiving maintenance treatment with IFX in five French referral centres were analysed retrospectively. Only patients who had endoscopic evaluation between 6 and 52 weeks following IFX initiation were included… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS
37 Citations
23 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial

  • R Panaccione, S Ghosh, S Middleton
  • J Crohn Colitis
  • 2011

The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease

  • JD Lewis
  • Gastroenterology
  • 2011

Similar Papers

Loading similar papers…